Bartel F, Pinkert D, Fiedler W, Kappler M, Würl P, Schmidt H, Taubert H
Institute of Pathology, Faculty of Medicine, University of Halle-Wittenberg, D-06097 Halle/Saale, Germany.
Int J Oncol. 2004 Jan;24(1):143-51. doi: 10.3892/ijo.24.1.143.
The MDM2 proto-oncogene encodes a 90-kDa protein that binds to and inactivates the tumor suppressor p53. Several reports describe the presence of different alternatively, as well as, aberrantly spliced transcripts of the MDM2 mRNA in a variety of human cancers that have lost the ability to bind p53. Due to the transforming ability of at least some of the isoforms it has been suggested that they might contribute to tumorigenesis. Here we show that shorter MDM2 transcripts are also widely expressed in normal tissues, including lung and renal tissue, and in lymphocytes. Alteration in MDM2 RNA transcripts were found in the majority of the samples. Although we cannot exclude that alterations in MDM2 preferentially occur during cancer development, our data rather indicate that in this context the commonly observed transcript variants may also possess a normal physiological function.
MDM2原癌基因编码一种90kDa的蛋白质,该蛋白质可与肿瘤抑制因子p53结合并使其失活。有几份报告描述了在多种已丧失结合p53能力的人类癌症中,存在不同的、选择性剪接以及异常剪接的MDM2 mRNA转录本。由于至少某些亚型具有转化能力,有人提出它们可能有助于肿瘤发生。在此我们表明,较短的MDM2转录本在包括肺和肾组织以及淋巴细胞在内的正常组织中也广泛表达。在大多数样本中发现了MDM2 RNA转录本的改变。虽然我们不能排除MDM2的改变在癌症发展过程中优先发生,但我们的数据更表明,在这种情况下,常见的转录本变体可能也具有正常的生理功能。